June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Preclinical profile of ISTH0036, a potent and selective antisense oligonucleotide targeting transforming growth factor beta 2 (TGF-β2) for the treatment of ophthalmic diseases
Author Affiliations & Notes
  • Katja Wosikowski
    Preclincial Research and Development, Isarna Therapeutics, Munich, Germany
  • Kathy Hasenbach
    Preclincial Research and Development, Isarna Therapeutics, Munich, Germany
  • Linda Allais
    WIL Research, Lyon, France
  • Pierluigi Fant
    WIL Research, Lyon, France
  • Nathalie Truchot
    WIL Research, Lyon, France
  • Monika Krampert
    Axolabs, Kulmbach, Germany
  • Ingo Roehl
    Axolabs, Kulmbach, Germany
  • Frank Jaschinski
    Preclincial Research and Development, Isarna Therapeutics, Munich, Germany
  • Hanna Korhonen
    Preclincial Research and Development, Isarna Therapeutics, Munich, Germany
  • Michel Janicot
    Preclincial Research and Development, Isarna Therapeutics, Munich, Germany
  • Footnotes
    Commercial Relationships Katja Wosikowski, Isarna Therapeutics (E); Kathy Hasenbach, Isarna Therapeutics (E); Linda Allais, WIl Research (E); Pierluigi Fant, WIL Research (E); Nathalie Truchot, WIL Research (E); Monika Krampert, Axolabs (E); Ingo Roehl, Axolabs (E); Frank Jaschinski, Isarna Therapeutics (E); Hanna Korhonen, Isarna Therapeutics (E); Michel Janicot, Isarna Therapeutics (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5714. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katja Wosikowski, Kathy Hasenbach, Linda Allais, Pierluigi Fant, Nathalie Truchot, Monika Krampert, Ingo Roehl, Frank Jaschinski, Hanna Korhonen, Michel Janicot; Preclinical profile of ISTH0036, a potent and selective antisense oligonucleotide targeting transforming growth factor beta 2 (TGF-β2) for the treatment of ophthalmic diseases. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5714.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: In ophthalmology, several diseases have been linked to the modulation of TGF-β expression. Specifically for TGF-β2, a critical role in the pathophysiology of glaucoma has been demonstrated, making this isoform a relevant therapeutic target for a disease which is the leading cause for irreversible blindness in the world. We developed a wide range of antisense oligonucleotides (ASO) based on the sequence of the human TGF-β2 mRNA. ISTH0036, a 14-mer phosphorothioate Locked Nucleic Acid-modified ASO gapmer, was selected for further testing.

Methods: In vitro, cells were treated with increasing concentrations of ISTH0036 or scrambled control ASO by gymnotic delivery. Cells were lysed and TGF-β2 mRNA levels were quantified by bDNA assay. TGF-β2 protein levels in cell supernatants were determined by ELISA. In vivo, ISTH0036 was administered via intravitreal (IVT) injection to eyes of several preclinical species. Ocular tissues were analyzed for tissue drug concentrations and target mRNA downregulation. The toxicity of ISTH0036 was tested in the rabbit following three IVT administrations at 2-week intervals.

Results: ISTH0036 shows potent and selective downregulation of target mRNA and protein in various cell-based assays. In vivo, fast distribution of ISTH0036 to the posterior tissues (choroid & retina, ciliary body & iris, optic nerve and sclera) was observed. The highest mean concentration (114 µg/g) of ISTH0036 was measured in the ciliary body & iris of the rabbit after 24 h of injection, followed by retina & choroid, optic nerve and sclera (30-40 µg/g). High drug concentrations in posterior eye tissues were observed up to 56 days after a single IVT injection. ISTH0036 induced in vivo TGF-β2 mRNA downregulation in choroid & retina, optic nerve and lens. Preclinical safety assessment of ISTH0036 in rabbits demonstrated good tolerability with only dose-related transient local inflammation and delayed lens opacification.

Conclusions: ISTH0036 demonstrated potent target TGF-β2 mRNA downregulation in cell-based assays and in relevant tissues of the eye in various preclinical species. Long-lasting posterior eye tissue distribution was consistent with the observed target engagement. This, combined with the limited toxicity findings in preclinical testing, supports a rapid advancement of ISTH0036 into clinical development.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×